We begin 2022 with a look at The Tisch Cancer Institute’s (TCI) latest discoveries by highlighting the work of our dedicated investigators. Their advances will bring our patients better health and longevity.
At Mount Sinai’s Vaccine and Cell Therapy Laboratory, we have created unique, individualized vaccines and shown their safety and promise. In another laboratory, investigator Jian Jin, PhD, and I have engineered a small molecule, MS21, which effectively targets the PTEN/AKT pathway, one of the most commonly mutated pathways in human cancer. Biopharmaceutical companies have been working to develop a drug that accomplishes this for two decades, but with limited success. We believe MS21 holds promise.
